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Abstract The abscopal effect refers to the ability of localized
radiation to trigger systemic antitumor effects. Over the past
50 years, reports on the abscopal effect arising from conven-
tional radiation have been relatively rare. However, with the
continued development and use of immunotherapy strategies
incorporating radiotherapy with targeted immunomodulators
and immune checkpoint blockade, the abscopal effect is be-
coming increasingly relevant in less immunogenic tumors
such as breast cancer. Here, we review the mechanism of the
abscopal effect, the current preclinical and clinical data, and
the application of the abscopal effect in designing clinical
trials of immunotherapy combined with radiotherapy in breast
cancer.
Keywords Breast cancer . Radiotherapy . Abscopal effect .
Immunotherapy
Introduction
Dr. RHMole first coined the term abscopal effect as “an action
at a distance from the irradiated volume but within the same
organism” in 1953 [1]. In oncology, the abscopal effect refers
to the ability of localized radiation to trigger systemic antitu-
mor effects. Over the past 50 years, the abscopal effect arising
from conventional radiation has been sparsely reported. A
recent review of 23 clinical cases of the abscopal effect after
radiotherapy (RT) alone noted that the majority of reported
cases occurred in immunogenic tumors such as renal cell car-
cinoma (RCC), melanoma, and hepatocellular carcinoma
(HCC) [2]. However, with the continued development and
use of immunotherapy strategies incorporating combinations
of targeted immunomodulators and immune checkpoint
blockade with radiotherapy, the abscopal effect is becoming
increasingly relevant in less immunogenic tumors such as
breast cancer. Here, we will review the mechanism of the
abscopal effect, the existing preclinical and clinical data, and
the use of the abscopal effect in designing clinical trials of
immunotherapy combined with RT in breast cancer.
Mechanism of the Abscopal Effect
The role of RT has historically focused on controlling and
eradicating local disease by maximizing direct tumor cell
damage and minimizing healthy tissue damage [3]. RT was
considered immunosuppressive secondary to reduced blood
counts, which were attributable to older techniques that in-
cluded large amounts of bonemarrow and/or circulating blood
volume within the radiation portals [4]. The role of total body
irradiation prior to stem cell transplantation is an example of
this concept in which lymphoablation and myeloablation are
induced, secondary to the inherent radiosensitivity of hemato-
poietic cells [5]. More recently, RT has been shown to pro-
mote a number of systemic immune modulatory effects on the
tumor as well. The abscopal effect is believed to arise from
local RT’s capacity to elicit these systemic immune effects to
control unirradiated tumor burden. RT acts as an immune
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modulator in the tumor microenvironment through several
mechanisms which will be elucidated in this review (Fig. 1).
Localized RT induces cell death and release of immuno-
genic factors via a process termed “immunogenic cell death”
(ICD), which subsequently triggers the release of a number of
endogenous damage-associated molecular patterns (DAMPs).
These DAMPs, which include calreticulin, high-mobility
group box 1 protein (HMGB1), and adenosine triphosphate
(ATP), contribute to the priming of the immune system by
triggering dendritic cells (DCs), thereby resulting in improved
antigen presentation to Tcells [6, 7]. Specifically, during ICD,
dying cells translocate calreticulin to the cell surface and are
processed by DCs, facilitating tumor antigen presentation and
cytotoxic T lymphocyte (CTL) stimulation [8]. The release of
HMGB1 acts as a pro-inflammatory mediator, stimulating
monocyte production of the cytokines TNF, IL-1, IL-6, and
IL-8 [9]. HMGB1 also improves tumor antigen presentation
by binding to Toll-like receptor 4 (TLR4) on DCs and
preventing the accelerated degradation of antigens within
DCs [4, 5, 10–12]. Released ATP binds to the purine receptors
on DCs, leading to inflammasome activation and IL-1β re-
lease [13]. Released DNA from dying cells can also activate
the stimulator of interferon gene (STING) pathway in DCs,
initiating type I interferon (IFN) production and enhancing
DC cross-priming [14].
RT has also been shown to stimulate tumor cell release of
chemokines CXCL16 and CXCL10, to increase the expres-
sion of adhesion molecules E-selectin and ICAM-1 in endo-
thelial cells and to upregulate major histocompatibility com-
plex (MHC1), Fas, ICAM-1, and NKG2D ligands [15–21].
Lastly, RT when combined with adoptive therapy may render
tumors accessible to infiltration and help normalize vascula-
ture in the tumor microenvironment [22]. Low-dose radiation
has also been reported to recruit NOS2-expressing
macrophages to the tumors, subsequently enhancing T cell
infiltration and normalizing tumor vasculature [23].
The infrequency of the abscopal effect in the clinical setting
is likely due to the counterbalance of the pro-immunogenic
signals generated by RT with the immunosuppressive effects
of RT. RT promotes TGF-β levels, recruitment of myeloid-
derived suppressor cells (MDSCs), and enrichment of regula-
tory T cells, which play an immunosuppressive role [24–27].
With broader use of targeted immunotherapy agents such as
the checkpoint inhibitors, TLR agonists, and cytokines in
combination with RT to stimulate the immune system, how-
ever, the abscopal effect is likely to be reported with increas-
ing frequency and in less immunogenic tumors.
Preclinical Reports of the Abscopal Effect
RTwith Immunostimulatory Molecules
Tumors subvert the immune system through a variety of local
and systemic processes, including overexpression of T cell
inhibitory signals, underexpression of costimulatory signals,
promotion of immune suppression of the microenvironment,
and lowering antigen presentation. A number of efforts in
combining RTwith immunotherapy have focused on the strat-
egy of enhancing immunostimulatory signals and blocking
inhibitory signals.
A large body of preclinical data has been published on the
use of RT with immunostimulatory molecules such as
interleukin-2 (IL-2), FMS-like tyrosine kinase 3 ligand (Flt3-
L), and Toll-like receptor (TLR) ligands to generate the
abscopal effect in mouse models of renal cell carcinoma,
breast cancer, and colon cancer.
Fig. 1 RT causes immunogenic cell death, leading to the release of
HMGB-1 and ATP and the translocation of CRT to the cell surface.
DCs bind to these molecules to further enhance antigen cross-
presentation and CTL priming. RT also promotes release of chemokines
CXCL10 and CXCL16 which attract T cells to the tumor. Macrophages
also release NO, stabilizing the local tumor vasculature. CRT calreticulin,
DC dendritic cells, CTL cytotoxic T lymphocyte, NO nitric oxide,
HMGB-1 high-mobility group box 1 protein, ATP adenosine triphosphate
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One of the first preclinical studies on the abscopal effect com-
bined RT with IL-2, a cytokine that plays a central role in lym-
phocyte activation and proliferation [28]. A mouse model of
RCC with pulmonary metastases was given either RT alone,
RTwith IL-2, or no treatment at all. The group found that local-
ized RT combined with IL-2 eliminated more pulmonary metas-
tases compared to localized RT alone. Yasuda et al. also investi-
gated the use of IL-2 in combination with radiation to treat a
mouse model of colon adenocarcinoma with metastases to the
liver [29]. Mice were treated locally with either RT, IL-2 alone,
RT with IL-2, or no treatment. The mice treated with combined
RT and IL-2 showed the largest decrease in the flank tumor size
and no metastatic lesions in the liver after 35 days.
Another immunostimulatory molecule that has been used
in combination with RT is Flt3-L, a growth factor for dendritic
cells. Chakravarty et al. implanted metastatic lung carcinoma
cells into the footpads of mice [30]. After 3 weeks, inoculated
mice had developed palpable tumors in their feet and
micrometastatic foci in the lungs. The foot tumors were then
irradiated with 60 Gy with or without intraperitoneally admin-
istered Flt3-L. Following irradiation of the mice’s footpads,
the number of pulmonary metastases was reduced, compared
to treatment with RT or Flt3-L alone. In another study,
Demaria et al. implanted mammary cancer cells bilaterally
into the flanks of mice [31]. The flanks were then irradiated
unilaterally, and Flt3-L was administered. Local RT alone
inhibited tumor growth on the irradiated side but not on the
unexposed side. When both RT and Flt3-L were given, how-
ever, both the irradiated and nonirradiated sides showed de-
layed growth.
TLR ligands have also been investigated in combination with
RT. Physiologically, TLRs recognize DAMPs and pathogen-
associated molecular patterns (PAMPs) and play a key role in
host defense by enhancing antigen presentation, promoting cyto-
kine production and upregulating costimulatory molecules on
DCs [32]. Dewan et al. used the TLR7 agonist imiquimod in
combination with RT in a mouse model of cutaneous breast
cancer [33]. The group injected breast cancer cells in primary
and secondary sites in mice. When imiquimod was topically
applied to the primary site alone, tumor growth was inhibited
in both primary and secondary tumor sites. When the primary
and secondary siteswere treatedwith imiquimod and the primary
site was irradiated, this inhibitory effect was further enhanced,
resulting in decreased tumor volumes in both the primary and
secondary sites.
RTwith Checkpoint Inhibitors
Physiologically, the immune checkpoints serve key roles in
moderating the inflammatory response in the setting of infec-
tion and self-tolerance. In the tumor microenvironment, these
immune checkpoints are often dysregulated and subvert the
host’s immune response to the tumor. The two most studied
immune checkpoint receptors are cytotoxic T lymphocyte-
associated protein 4 (CTLA-4) and programmed cell death-1
(PD-1). CTLA-4 regulates the early stages of T cell activation
by limiting activating signals from the T cell co-stimulatory
receptor CD28 by competitively binding to shared ligands
CD80 and CD86. PD-1 helps limit the inflammatory response
of effector T cells in the peripheral tissue through binding of
its ligands PD-L1 and PD-L2.
One of the first preclinical investigations combining RT
and immune checkpoint blockade used a poorly immunogenic
metastatic mammary mouse carcinoma cell line [34]. Anti-
CTLA-4 antibodies, RT, the combination of CTLA-4 antibod-
ies and RT, or no treatment were administered to mice injected
with 4T1 cancer cells in their flank. Although CTLA-4 block-
ade alone did not alter tumor growth or survival, the combi-
nation of RT and checkpoint blockade delayed growth of the
primary irradiated tumor, increased survival, and inhibited
lung metastases formation. CTLA-4 blockade with one frac-
tion of 12 Gy gave a statistically significant increase in surviv-
al times but not statistically significant primary tumor control
compared to RT alone. Two fractions of 12 Gy given at 48-h
intervals, however, resulted in complete tumor regression and
longer survival in the majority of treated mice. A subsequent
study by Dewan et al. investigated the abscopal effect further
by using the TSA breast cancer and the MCA38 colon cancer
mouse models. The group implanted either TSA or MCA38
cells into the flanks of mice bilaterally [35]. They then irradi-
ated one side of the mice and administered anti-CTLA-4 anti-
bodies. Growth was delayed not only on the irradiated side but
also on the nonirradiated side. Treatment with anti-CTLA4
antibodies alone had no effect on the implanted tumors.
Zeng et al. tested anti-PD-1 antibodies with RT in a mouse
glioblastoma multiforme model [36]. They implanted glioma
cells intracranially into mice and treated the mice with either
sham treatment, anti-PD-1 antibody, RT, or RTwith anti-PD-1
antibody. Median survival was highest in the RTwith the anti-
PD-1 antibody group. Similarly, enhanced tumor control and
intratumoral T cell infiltration have also been reported in mel-
anoma and breast cancer mouse models treated with a combi-
nation of RT and anti-PD-1 antibody [37]. Another group also
explored the triplet combination of RT, CTLA-4 inhibition,
and PD-L1 in a melanoma mouse model [38•]. They found
that while tumors responded to RT and anti-CTLA4, resis-
tance remained common due to upregulation of PD-L1 on
melanoma cells. When PD-L1 was added to the resistant mel-
anoma cells, tumor volume decreased further.
Clinical Reports of the Abscopal Effect
Clinical evidence of the abscopal effect reported by
Postow et al. in a metastatic melanoma patient treated
with ipilimumab and radiotherapy [39]. While on
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ipilimumab as maintenance therapy, the patient received
28.5 Gy in three fractions as palliative RT for right-sided
back pain from a paraspinal mass. Four months after RT,
the paraspinal mass had regressed along with nonirradiat-
ed lesions in the right hilar lymph node and spleen. Ten
months after RT, repeat CT scan showed stable, minimal
disease. Another case report described a metastatic mela-
noma patient treated with 54 Gy in three fractions in ad-
dition to ipilimumab who achieved a complete response
of all his metastases, including unirradiated liver and ax-
illary lesions [40]. A phase I/II clinical study of 34 pa-
tients with metastatic castration-resistant prostate cancer
treated with ipilimumab and 8 Gy fractions on up to three
bone metastases reported a complete response in one pa-
tient, stable disease in six patients, and prostate-specific
antigen declines of ≥50% [41]. Golden et al. recently
completed a study of the abscopal effect after administer-
ing GM-CSF along with 3.5 Gy× 10 to patients with met-
astatic solid tumors [42•]. The group reported abscopal
responses in 11 of the 41 enrolled patients. Of note, 5 of
14 breast cancer patients had an abscopal response.
Radiation Dose, Fraction, and Timing
To date, there is no established consensus on the optimal dose,
fraction, and timing of RT to combine with immunomodulation
to generate an abscopal response based on preclinical studies.
Whereas some studies have supported the efficacy of a single
dose of radiation ranging from 0.5 to 25 Gy in inhibiting tumor
growth, others have demonstrated that standard doses of 2 Gy or
smaller hypofractionated doses of 6 or 8 Gy are more effective
than a single large dose [20, 23, 43–45].
Lee et al. reported that when mouse melanoma tumors
were treated with 5 Gy× 4 over 2 weeks, the tumors ini-
tially responded to RT but subsequently relapsed [46]. In
contrast, when Dewan et al. used radiation regimens of
20 Gy× 1, 8 Gy× 3, and 6 Gy× 5 in combination with
anti-CTLA-4 antibody, they found that the fractionated
doses were more effective in inhibiting tumor growth out-
side of the field of radiation compared to the single-dose
regimen [35]. A single institution review of 47 metastatic
melanoma patients treated with ipilimumab and radiation
found a significant association with abscopal responses
Table 1 Clinical trials using CTLA4/PD1/PDL1 inhibitors and RT for breast cancer
Agent Conditions Sponsor Status Clinicaltrials.gov
ID
Radiotherapy with CTLA4 inhibitors
Tremelimumab with brain irradiation Breast cancer with brain
metastases






Radiotherapy with PD1/PDL1 inhibitors












Pembrolizumab and 20 Gy× 1 (SABR) Oligometastatic breast
cancer






Durvalumab with Tremelimumab and 8 Gy × 3
fractions vs 17 Gy× 1 fractiona






Nivolumab given after either 20 Gy× 1, low-dose
doxorubicin, cyclophosphamide, cisplatin,
or no induction treatment








Radiotherapy with miscellaneous immunotherapy
LY2157299 (TGF-β receptor type 1 kinase
inhibitor) and 7.5 Gy× 3





with 6 Gy× 5






MEDI6469 (monoclonal antibody to OX40)
with RT of 15, 20, or 25 Gy to lung or
liver metastases
Metastatic breast cancer







TNBC triple-negative breast cancer, RT radiotherapy, SABR stereotactic ablative radiotherapy
a Part of a larger trial
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with multiple fraction regimens, specifically with radia-
tion fraction sizes of ≤3 Gy [47].
Investigations are ongoing with regard to the optimal se-
quencing of checkpoint blockade relative to radiotherapy ad-
ministration. One study reported no association between
abscopal responses in either duration from the first dose of
ipilimumab to initial radiation treatment or timing of
ipilimumab relative to RT [47].
The size of the irradiated target volume may also play in a
role in determining the degree of abscopal response. Larger
tumors have been hypothesized to release a larger number and
variety of neoantigens upon irradiation [48]. However, larger
tumors may also shelter deeper hypoxic areas that are immu-
nosuppressive and radioresistant.
Clinical Trials of Immune Therapy and RT in Breast
Cancer
Based on the promising results of preclinical trials dem-
onstrating the enhancement of the abscopal effect with
combinations of immunotherapy and RT, several clinical
trials testing the combination in breast cancer patients are
actively ongoing (summarized in Table 1). The Memorial
Sloan Kettering Cancer Center is recruiting patients with
metastatic triple-negative breast cancer (TNBC) patients
for a treatment regimen combining pembrolizumab with
five fractions of 6 Gy [49]. Patients must have at least two
tumors measurable by Response Evaluation Criteria in
Solid Tumors (RECIST) criteria, one of which must re-
quire palliative radiation. Patients with active brain metas-
tases are excluded. The majority of the 10 patients treated
to date in the trial have been irradiated at visceral organ
sites. The University of Pennsylvania is comparing two
radiation schedules of either three fractions of 8 Gy radi-
ation or one fraction of 17 Gy, in combination with
tremelimumab and durvalumab, for metastatic breast can-
cer patients [50]. In a phase 2 trial, the Netherlands
Cancer Institute is comparing nivolumab in combination
with either one fraction of 20 Gy, cyclophosphamide,
low-dose doxorubicin, or cisplatin in TNBC patients
[51]. The Peter MacCallum Cancer Centre in Australia
is also running a phase 1 study examining the effects of
pembrol izumab wi th one frac t ion of 20 Gy in
oligometastatic breast cancer [52]. A phase 2 study com-
bining an anti-TGF-β blocker with three fractions of
7.5 Gy in metastatic breast cancer of all subtypes is ac-
cruing at Weill Cornell and University of California Los
Angeles [53]. The Portland Providence Medical Center is
also exploring the use of single-dose stereotactic body
radiation therapy (SBRT) prior to administration of an
OX40 inhibitor in breast cancer patients with metastases
to the liver and lungs [54]. Finally, a study of TLR-7
agonist and cyclophosphamide combined with RT
(6 Gy× 5 fractions) for breast cancer patients with skin
metastases is ongoing at New York University Medical
Center [12].
Future Directions
Exploiting the abscopal effect in breast cancer is intrigu-
ing, allowing for both local and systemic control of tumor
disease burden. Previously, the abscopal effect with RT
alone was a relatively rare event. However, with the
development of new immunotherapies that further en-
hance the immune response, the abscopal response is like-
ly to become more clinically meaningful. Current chal-
lenges include optimizing radiation doses to maximize
immune stimulation, determining the most favorable radi-
ation sequence, defining the optimal combination of
immunostimulatory molecules to use alongside radiation,
and further neutralizing the immunosuppressive elements
that accompany RT. Further progress in the use of
abscopal effect in breast cancer will also require the trans-
lation of preclinical data into relevant clinically applicable
treatments and the development of evidence-based con-
sensus guidelines. For instance, whereas the majority of
preclinical models have used mouse models in which ra-
diation is delivered to tumors implanted into subcutaneous
tissues, the aforementioned clinical reports of the abscopal
effects have largely stemmed from irradiation of visceral
metastases [7, 8]. If the abscopal effect is to be harnessed
into an effective treatment, multidisciplinary collaboration
with radiation oncology, laboratory research, and medical
oncology in the optimal design of clinical trials of immu-
notherapy and RT will be required.
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